Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016 by Beeton, Michael L et al.
1www.eurosurveillance.org
Research
Mycoplasma pneumoniae infections, 11 countries in 
Europe and Israel, 2011 to 2016
Michael L Beeton¹, Xu-Sheng Zhang2, Søren A Uldum³, Cécile Bébéar⁴, Roger Dumke⁵, Karolina Gullsby⁶, Margareta Ieven⁷, 
Katherine Loens⁷, Ran Nir-Paz⁸, Sabine Pereyre⁴, O Brad Spiller⁹, Victoria J Chalker2, the ESCMID Study Group for Mycoplasma 
and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae subgroup10
1. Department of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, United Kingdom
2. Public Health England, London, United Kingdom
3. Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
4. USC-EA 3671, Mycoplasmal and Chlamydia Infections in Humans, University of Bordeaux, Bordeaux, France
5. TU Dresden, Dresden, Germany
6. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden
7. Antwerp University Hospital Edegem, Belgium
8. Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
9. Department of Medical Microbiology, Division of Infection and Immunity, Cardiff University, School of Medicine, Cardiff, United 
Kingdom
10. ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae subgroup members are 
listed at the end of the article
Correspondence: Victoria Chalker (vicki.chalker@phe.gov.uk)
Citation style for this article: 
Beeton Michael L, Zhang Xu-Sheng, Uldum Søren A, Bébéar Cécile, Dumke Roger, Gullsby Karolina, Ieven Margareta, Loens Katherine, Nir-Paz Ran, Pereyre 
Sabine, Spiller O Brad, Chalker Victoria J, the ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae subgroup. 
Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill. 2020;25(2):pii=1900112. https://doi.org/10.2807/1560-7917.
ES.2020.25.2.1900112 
Article submitted on 11 Feb 2019 / accepted on 15 Jul 2019 / published on 16 Jan 2020
Background: Mycoplasma pneumoniae is a leading 
cause of community-acquired pneumonia, with large 
epidemics previously described to occur every 4 to 7 
years. Aim: To better understand the diagnostic meth-
ods used to detect M. pneumoniae; to better under-
stand M. pneumoniae testing and surveillance in use; 
to identify epidemics; to determine detection number 
per age group, age demographics for positive detec-
tions, concurrence of epidemics and annual peaks 
across geographical areas; and to determine the effect 
of geographical location on the timing of epidemics.
Methods: A questionnaire was sent in May 2016 to 
Mycoplasma experts with national or regional respon-
sibility within the ESCMID Study Group for Mycoplasma 
and Chlamydia Infections in 17 countries across Europe 
and Israel, retrospectively requesting details on M. 
pneumoniae-positive samples from January 2011 to 
April 2016. The Moving Epidemic Method was used 
to determine epidemic periods and effect of coun-
try latitude across the countries for the five periods 
under investigation. Results: Representatives from 12 
countries provided data on M. pneumoniae infections, 
accounting for 95,666 positive samples. Two laborato-
ries initiated routine macrolide resistance testing since 
2013. Between 2011 and 2016, three epidemics were 
identified: 2011/12, 2014/15 and 2015/16. The distribu-
tion of patient ages for M. pneumoniae-positive sam-
ples showed three patterns. During epidemic years, 
an association between country latitude and calendar 
week when epidemic periods began was noted.
Conclusions: An association between epidemics and 
latitude was observed. Differences were noted in the 
age distribution of positive cases and detection meth-
ods used and practice. A lack of macrolide resistance 
monitoring was noted.
Introduction
Mycoplasma pneumoniae is a major cause of respiratory 
infection in humans and macrolide antibiotics, such 
as azithromycin, are used as the first-line of treat-
ment in many countries. The bacterium is transmit-
ted from person-to-person by respiratory droplets 
with the incubation period ranging from 4 days to 3 
weeks [1]. Because of M. pneumoniae’s intrinsic resist-
ance to many antibiotics, including all cell wall inhibi-
tors, macrolide antibiotics such as azithromycin and 
clarithromycin are the drug of choice for treatment. In 
cases of suspected infection in immunocompromised 
individuals, bactericidal fluoroquinolones may be con-
sidered. Tetracyclines are an alternative for treatment 
of adults with possible macrolide-resistant  M. pneu-
moniae infections. Prudent use of antibiotics has been 
urged for all cases of M. pneumoniae infection because 
of worldwide reports of macrolide resistance, which 
have been reported as ranging from 0.2% in Sweden to 
more than 90% in China [2-5].
M. pneumoniae  infections show seasonal variation. 
In temperate climates, the number of infections peak 
during the latter months of the years, with epidemic 
periods every 4 to 7 years on average [6-8]. The most 
2 www.eurosurveillance.org
Table 1
Mycoplasma pneumoniae detection methods, percent of positive samples and macrolide resistance monitoring by country, 
11 countries in Europe and Israel, 2011–2016
Country
Nucleic acid 
amplification test Culture Serology
Total 
number 
of 
positive 
samples
Total 
number 
of 
negative 
samples
Percent of 
positive 
samples 
(%)
Macrolide 
resistance 
monitoringPerformed
Number of 
positive 
detections
Performed
Number of 
positive 
detections
Performed
Number of 
positive 
detections
Belgium Yes 894 Yes 49 Yes 12,047 21,094a ND NA
Only monitored 
when samples 
test positive 
at the NRC. 
No testing 
in sentinel 
laboratories.
Denmark Yes 20,081 No NA No NA 20,081 264,770 7.0
No routine 
surveillance 
system in place. 
In 2010/11, 
2011/12 and 
2015/16, 809 
samples were 
examined 
identifying 
13 macrolide 
resistance-
associated 
mutations 
(1.5%). Samples 
are investigated 
upon physician 
request.
France Yes 92 Yes 53b Yes 298 390 7,463 5.0
Performed 
on all clinical 
specimens 
detected as M. 
pneumoniae-
positive by 
NAAT since 
2013 [13].
Germany Yes 127 No NA Yes 316 443 10,143 4.2 No comment
Greece No NA No NA Yes 140 140 1,498 8.5 Information not provided
Hungary Yes 17 No NA Yes 1,117 1,134 6,109 15.7 Information not provided
Ireland No NA No NA Yes 535 535 2,853 15.8 Information not provided
Israel Yes 848 No NA No NA 848 5,309 13.8 No active monitoring.
Norway Yes 13,980 No NA Yes 10,678 24,658 ND NA Information not provided
Slovenia Yes 1,172 Yes 827 No NA 1,172 8,872 11.7
Only upon 
physician 
request
Sweden Yes 9,499 No NA Yes 10,024 19,523 169,501 10.3 No active monitoring.
United 
Kingdom 
(excluding 
Northern 
Ireland)
Yes 385 No NA Yes 5,263 5,648 ND NA
No national 
system. All 
positive 
samples 
referred to PHE 
are tested.
Total NA 47,095 NA 876 NA 40,418 95,666 476,518 NA NA
NA: not applicable; NAAT: Nucleic acid amplification test; ND: no data available; NRC: National Reference Centre; PHE: Public Health England.
a Method of detection not known for sentinel laboratories.
b Not included in the overall total for the purpose of de-duplication as these 53 samples were already listed in NAAT or serological counts.
Responses were received to state M. pneumoniae testing and surveillance is not in place on a national scale or case data were not available 
within the timespan of the survey from European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for 
Mycoplasma Infections (ESGMI) members from Cyprus, Malta, the Netherlands, Poland, Slovakia or Spain.
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Figure 1
Four weekly moving average data on Mycoplasma pneumoniae infections by detection methods, 11 countries in Europe and 
Israel, 2011–2016
B. Confirmations determined by NAAT from 10 countries
     (n = 47,095)a
A. Total number of detections from 12 countries
D. Culture from two countriesa (n = 876)c C. Serology from nine countries (n = 40, 418)b
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NAAT: nucleic acid amplification tests.
a Ten countries: Belgium, Denmark, France, Germany, Hungary, Israel, Norway, Slovenia, Sweden and the United Kingdom (excluding Northern 
Ireland).
b Nine countries: Belgium, France, Germany, Greece, Hungary, Ireland, Norway and Sweden and the United Kingdom (excluding Northern 
Ireland).
c Two countries: Belgium and Slovenia. Culture data from France not included as it was duplicated in NAAT and serological data.
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recent survey in 2012 by Lenglet et al indicated that 
some countries in the European Union and European 
Economic Area experienced an increase in M. pneumo-
niae  cases in 2011 whereas others did not, indicating 
that a universal geographic increase had not occurred 
[5]. Little is understood about the transmission of  M. 
pneumoniae  within populations and several factors 
have been postulated to account for transmission 
dynamics, including the immunity level of the 
population, the bacterial population based on the P1 
adhesin type, the age and extent of mixing of children 
in educational settings.
Methodologies for detection of M. pneumoniae include 
nucleic acid amplification tests (NAAT), serology and 
culture with varying sensitivities and specificities. 
There is no international standard material for quality 
control detection in assays, although external quality 
control schema exist for some methodologies (NAAT). 
There are no internationally defined guidelines on 
the requirements for surveillance of  M. pneumoniae, 
macrolide resistance testing and surveillance, refer-
ence system structure, routine testing and bacterial 
strain discrimination. However, a few countries such 
as France and the United States (US) have surveillance 
within specific regions and national surveillance is 
seen in countries such as Denmark [9] and Japan, the 
latter of which has maintained an active surveillance 
system for this pathogen for some time [10]. Overall, 
laboratory confirmed cases and surveillance data 
regarding the number of cases and reported cases of 
macrolide resistance are likely to be underestimated. 
This is further confounded because an undefined pro-
portion of patients will have mild disease or may be 
carriers within community settings, without active test-
ing to confirm the infection. Further underestimation is 
likely to occur from patients receiving empirical treat-
ment in the absence of laboratory-confirmed infection 
with M. pneumoniae.
In response to an increase in infection seen in several 
countries in 2016, the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) Study 
Group for Mycoplasma Infections (ESGMI), now called 
the Study Group for Mycoplasma and Chlamydia 
Infections (ESGMAC), established this study [9,11]. The 
purpose of the study was to gain a greater understand-
ing of the diagnostic methods used to detect M. pneu-
moniae; gain a greater understanding of the testing 
and surveillance in use for  M. pneumoniae  (macrolide 
resistance, seasonality); to identify epidemics; to 
determine detections per age group, age demographics 
for positive detections and concurrence of epidemics 
and annual peaks across geographical areas; and to 
determine the effect of geographical location on timing 
of epidemics.
Methods
Study type, data collection and analysis
ESGMI conducted a retrospective email-based survey 
in May 2016 of ESGMI members in countries in Europe 
and Israel, asking members to describe existing labora-
tory-confirmed case data for M. pneumoniae infection. 
This retrospective study involved sending an email-
based survey to 18 experts collating laboratory-con-
firmed documented detections of M. pneumoniae from 
national laboratory and surveillance institutions 
or, if not available, other regional laboratory and 
surveillance institutions.  Mycoplasma experts invited 
to participate in the study were either active members 
of ESGMI or authors listed in the previous study by 
Lenglet et al [5]. Participants were invited to join the 
study and provide the number of detections confirmed 
by nucleic acid amplification test (NAAT), serology, 
culture and total overall between weeks commencing 
3 January 2011 to 24 April 2016. Positive results and, 
if available, negative results were also collated. For 
Germany and France, only regional data were available.
Additional information was requested, including what 
diagnostic methods were used to detect  M. pneumo-
niae; whether surveillance for  M. pneumoniae  was in 
use; if macrolide resistance was being monitored by 
countries; and  M. pneumoniae  detection number per 
age group.
Data from each participating country was collated and 
aggregated to give total number of detections per age 
group and four weekly moving averages of detections 
per country and overall where possible. We did not 
request information on the sex of patient from which 
detections were made. Total weekly data were subcat-
egorised by age group: 0 to 4 years, 5 to 9 years, 10 to 
14 years, 15 to 24 years, 25 to 44 years, 45 to 64 years, 
≥ 65 years or unknown.
Case definition
Cases of  M. pneumoniae  infection were defined by 
local practice. Because of local variation, this study 
collated information on M. pneumoniae detections, not 
cases.
De-duplication and exclusion criteria
Because of the heterogeneous nature of  M. pneu-
moniae  data collection from each country, defining 
study-wide de-duplication criteria was not feasible. 
Participants were therefore asked to detail if data with 
duplicate samples from the same patient (e.g. with 
NAAT and serology) was included as a single category 
and if possible, to include as serology. Specific 
exclusion criteria were also not set for similar reasons 
stated above. Responses for de-duplication and 
exclusion criteria are listed in Supplementary Table S1.
Characteristics of epidemics using the Moving 
Epidemic Method
To determine the characteristic properties of M. pneu-
moniae  epidemics across the 12 countries for which 
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Figure 2
Analysis of Mycoplasma pneumoniae epidemic periods using the Moving Epidemic Method, 11 countries in Europe and 
Israel, 2011–2016
B. Week 19 2012- week 18 2013 (n = 11,089)A. Week 19 2011-week 18 2012 (epidemic year)  (n = 35,747)
D. Week 19 2014-week 18 2015 (epidemic year)  (n = 15,312)C. Week 19 2013-week 18 2014 (n = 8,510)
E. Week 19 2015-week 17 2016 (epidemic year) (n = 19,439)
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MEM: Moving Epidemic Method.
Week numbers represent epidemic week period (week 1 represents calendar week 19). Green dots represent pre-epidemic period, purple dots 
represent epidemic period and yellow dots represent post-epidemic period, as calculated by the MEM.
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data were provided on  M. pneumoniae  positivity, the 
Moving Epidemic Method (MEM) was used [12]. An epi-
demic slope threshold of 2% was chosen and used to 
determine the pre-epidemic period, epidemic period 
and post-epidemic period for the five periods coincid-
ing with annual peaks spanning week 19 of the first 
year through week 18 of the following year. These data 
were used to calculate the epidemic duration for each 
country, as well as the percentage of positive samples 
that were identified within this period. Data generated 
from the MEM model, such as week number in which 
epidemics began, were used to correlate the onset of 
epidemics with the geographical location of each coun-
try. Statistical analysis for generating p values and cal-
culation of r2 were performed with GraphPad Prism 5.0.
Ethics statement
This retrospective study involved collation of 
anonymised surveillance data for epidemiological anal-
ysis. Ethical approval was not required and no patient 
identifiers were included in the study.
Results
Of the 18 countries approached, 11 countries across 
Europe and Israel, provided information regarding  M. 
pneumoniae. For Cyprus, Malta, the Netherlands, 
Poland, Slovakia and Spain,  M. pneumoniae  national 
testing and surveillance systems were not in place or 
a response with data was not received within the time-
frame of the study.
Mycoplasma pneumoniae detection methods
During the study period, a total of 95,666 detections 
of  M. pneumoniae  were confirmed from participating 
countries (Table 1). The method of  M. pneumo-
niae  detection varied between the 12 countries. Two 
countries, Denmark and Israel, reported exclusively 
NAAT use; two countries, Greece and Ireland, reported 
serology exclusively; five countries, Germany, Hungary, 
Norway, Sweden and the United Kingdom (excluding 
Northern Ireland) used a combination of NAAT 
and serology; one country, Slovenia, used NAAT in 
combination with culture; and two countries, Belgium 
and France, used all three methods. No country relied 
on culture alone (Table 1).
The greatest number of positive samples were reported 
using NAAT (47,095; 49%) followed by serology 
(40,418; 42%). Only 876 (1%) samples were reported 
positive by culture and 7,277 (8%) of tests were not 
specified. Norway contributed the greatest number 
of  M. pneumoniae-positive detections to the total fig-
ure (24,658; 26%) and Greece the lowest (140; 0.1%). 
De-duplication data were determined at country level 
(Supplementary Table S1).
Macrolide resistance monitoring
With regards to active monitoring of macrolide resist-
ance, five countries did not comment; Belgium noted 
that monitoring was only carried out on positive sam-
ples identified at the National Reference Laboratory, 
but not at sentinel laboratories; Slovenia noted that 
macrolide resistance determination was carried out 
only upon physician request; in this study, Denmark 
stated that NAAT-positive samples from three recent M. 
pneumoniae  epidemic periods were investigated, 
finding a low level (1.5%) of macrolide resistance, 
and that clinical samples are investigated on request 
from physicians; the Mycoplasmal and Chlamydia 
Infections in Humans Research Department, University 
of Bordeaux, France initiated national systematic moni-
toring of all NAAT-positive clinical specimens in 2013 
using an in-house published method [13]. In 2017, 
England and Wales introduced monitoring of all posi-
tive NAAT samples referred to the National Reference 
Laboratory. Two countries stated that no monitoring for 
resistance was in place (Table 1).
Total number of detections and seasonality
The distribution and seasonality of the 95,666 detec-
tions from the 12 countries across the study period was 
determined. To account for weekly bias in reporting, 
data were converted to four weekly moving average. 
The greatest number of positive samples from the four 
weekly moving average data was 1,759 positive detec-
tions during week 48 of 2011.
Detection of M. pneumoniae by NAAT correlated with the 
overall detections (Figure 1A and Figure 1B). Detection 
of M. pneumoniae by culture accounted for the lowest 
number of positive samples per methodology; 1% of 
the total positive samples. Detection using serology 
was the second most common method for detecting M. 
pneumoniae-positive patients (Figure 1C). The four 
weekly moving average for detection by culture (Figure 
1D) was less than five positive samples for all reporting 
weeks with the exception of Slovenia in the 2015 sea-
son when a maximum average of 52 positive samples 
was identified.
Epidemic periods based on the Moving 
Epidemic Method
Analysis of detections during the annual periods was 
carried out using MEM (Figure 2). For the five annual 
periods described, we noted 35,747; 11,089; 8,510; 
15,312; 19,439 detections for the periods 2011/12, 
2012/13, 2013/14, 2014/15 and 2015/16, respectively. 
Three epidemics were detected between 2011/12, 
2014/15 and 2015/16, in which 67%, 59% and 68% of 
each period’s detections were identified during the cal-
culated epidemic period, respectively. Epidemics had 
longer duration, 19, 21 and 23 weeks, respectively, 
compared with the duration observed during annual 
seasonal peaks of infection (non-epidemic periods). In 
2012/13, the duration was 13 weeks with 30% of total 
detections and in 2013/14, 15 weeks with 35% of total 
detections. For countries providing the total number 
of negative samples, the percentage of positive sam-
ples identified during the pre-epidemic, epidemic and 
post-epidemic period was calculated for the epidemic 
periods of 2011/12, 2014/15 and 2015/16 (Table 2). For 
all periods, there was a greater percentage of positive 
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samples during the epidemic period than in the pre-
epidemic period.
Correlation between latitude and epidemic 
period onset
When examining the epidemic periods of 2011/12, 
2014/15 and 2015/16, a clear association between the 
country latitude and beginning of the national epi-
demic period was observed (Figure 4). This was sta-
tistically significant for the 2011/12 period (p < 0.005; 
r2 = 0.92) and the 2014/15 period (p < 0.005; r2 = 0.84). 
However, significance was not achieved during the 
2015/16 period (p = 0.1; r2 = 0.38). The association 
was most apparent during the major epidemic period 
of 2011/12 when the epidemic period was first noted 
in Norway (60.4oN) during epidemic week 22 (calendar 
week 40 of 2011) and was then observed to start in 
Israel (31oN) during epidemic week 43 (calendar week 
9 of 2012). There was a lack of an association during 
Figure 3
Number of Mycoplasma pneumoniae detections by age group, 10 countries in Europea and Israel, 2011–2016 (n = 70,191)
1,000
3,000
2,000
5,000
4,000
Belgium
Age group (years)
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
Nu
m
be
r o
f c
as
es
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
Age group (years)
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
Age group (years)
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
Age group (years)
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5 0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
0−
4
5−
9
10
−1
4
15−
24
25
−4
4
45
−6
4
≥6
5
Age group (years)
Age group (years) Age group (years) Age group (years)
Age group (years) Age group (years)
Age group (years)
1,000
3,000
5,000
4,000
2,000
Denmark
40
60
80
100
France
20
60
40
80
100
120
Germany
600
800
1,000
1,200
United Kingdom (excluding
Northern Ireland)
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b Ireland did not test for M. pneumoniae in patients 25 years of age and above.
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the non-epidemic periods of 2012/13 and 2013/14 (data 
not shown). 
Discussion
Our study involved assembling the largest dataset thus 
far of M. pneumoniae-positive samples and associated 
data on the methods used to detect M. pneumoniae per 
country. NAATs were the most common method used 
among the 12 countries. A variety of commercial and 
in-house methodologies were used in the detection 
of M. pneumoniae in our study. However, a recent study 
of 13 assays used across Europe, Israel and the US 
demonstrated comparable levels of detection of 20 M. 
pneumoniae  genomes per reaction [14]. Serological 
methods were also commonly used to detect M. pneu-
moniae  infections. The presence of an IgM response 
may indicate recent acquisition of infection, but it may 
be an unreliable marker because of documented long-
term persistence of antibodies [15]. Culture-dependent 
methods were used by three countries. Culture has 
the benefit of confirming the presence of viable  M. 
pneumoniae  and may permit phenotypic antimicrobial 
susceptibility testing. However, because of the 
considerable time required for growth, up to 4 weeks, 
it does not provide results within a clinically relevant 
time period.
Currently, no single method is recommended for rou-
tine detection of  M. pneumoniae,  and international 
guidelines or control materials do not exist. Real-time 
PCR and serology have previously shown agreement in 
their ability to detect  M. pneumoniae  among samples 
(90% agreement), however, 7% of patients were PCR 
positive, with limited evidence of seroconversion 
[16]. No single test can reliably detect all infections. 
Therefore, a combined approach utilising both NAAT 
and serology may help to identify any potential false-
negative results, with NAAT used for acute phase 
detection [17].
In addition to method of detection, we sought to 
identify if surveillance for macrolide resistance was 
routinely undertaken. Routine macrolide resistance 
monitoring was not systematically in place. This may 
contribute to the under-detection of resistance or 
reflect low levels of macrolide resistance reported 
across Europe [18-20]. High levels of resistance have 
been noted, for example, in Israel (30%) [21] and China 
wherein reported macrolide resistance levels are 90 to 
100% [22,23]. High incidence of macrolide resistance 
necessitates co-ordinated surveillance across Europe. 
It would be of benefit to increase physicians’ knowl-
edge of macrolide resistance rates and acquisition, as 
well as an understanding of the patient’s recent travel 
history when considering therapy. In the authors’ opin-
ion, co-ordinated international surveillance for mac-
rolide resistance should be considered as macrolides 
are the current treatment of choice in Europe.
Regardless of the methodology used to detect M. pneu-
moniae, clear seasonal trends were apparent between 
January 2011 and April 2016, with peaks in infection 
occurring between the fourth quarter of a year and first 
quarter of the next. To calculate the epidemic period for 
each season, the MEM, as described by Vega et al, was 
used [12]. Three clear epidemics were noted in 2011/12, 
2014/15 and 2015/16.  M. pneumoniae  epidemics have 
been suggested to occur every 4 to 7 years, lasting for 
longer than one annual season in some cases [8,24]. 
However, in this study, based on a very large data set, 
the interval between epidemic occurrence was found 
to be 3 years from 2011/12 to 2014/15 and 1 year from 
2014/15 to 2015/16. The latter epidemic period may 
reflect a secondary peak of cases within a 2-year epi-
demic span as previous epidemics have been shown to 
persist for some time [5,24]. Confirmation of circulating 
genotypes of  M. pneumoniae  from large geographical 
areas would be of interest to determine the microbio-
logical nature of strains within these and epidemic 
periods.
Figure 4
Correlation between country latitude and epidemic week for Mycoplasma pneumoniae infections, 7 European countries and 
Israel, epidemic periods 2011/12, 2014/15 and 2015/16
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Countries in which epidemic periods began prior to that predicted by the Moving Epidemic Method were removed from the analysis. A 
statistically significant association between the week in which the country epidemic began and epidemic week number was seen in 2011/12 (p 
< 0.005; r2 = 0.92) and 2014/15 (p < 0.005; r2 = 0.84). No significant association was seen in 2015/16 (p = 0.1; r2 = 0.38).
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For the major epidemic periods, we sought to deter-
mine any changes between the pre-epidemic, epidemic 
and post-epidemic periods in the reported number of 
detections in countries reporting both positive and 
negative data. The greatest rise was seen in Ireland 
where 18% of samples were positive for  M. pneu-
moniae  in the pre-epidemic period, while 30% were 
positive during the epidemic period in 2011/12. In 
Denmark, France, Slovenia and Sweden, the prevalence 
in the post-epidemic period was lower than that of the 
pre-epidemic period in 2011/12. This lower prevalence 
in the post-epidemic period may reflect over-sampling 
as a bias resulting from higher prevalence during the 
epidemic. This may also reflect an increase in the 
population burden of infection prior to an epidemic. 
Additional analysis is required to understand if this is 
the case and if monitoring of levels can be used to pre-
dict imminent epidemics.
A notable observation was the pattern of positive 
detections stratified by age, with detections in all age 
groups.  M. pneumoniae  cases are classically seen 
among children 5 to 14 years of age, with those under 5 
years experiencing milder disease [17]. This trend was 
seen in Germany, Greece, Ireland and Slovenia which 
skew towards the younger age groups. For Greece, this 
can be attributed to the acquisition of samples from 
a tertiary children’s hospital in Athens. It should be 
noted that the skew towards younger age groups seen 
in Ireland may reflect the nature of only investigating 
patients up to 25 years of age. An observed peak in 
infection among the under 14 years age groups was fol-
lowed by a second peak in the 25 to 44 years age group 
giving a bimodal distribution in five countries. Finally, 
a skew to the older age groups was seen in Hungary 
and Sweden. This observation is not likely to be an 
artefact of testing methodology whereby older people 
may be more likely to have existing IgM levels as both 
countries do not solely rely on serology. The reason for 
this increased detection in people above 44 years of 
age in two countries is unknown; it may simply reflect 
differences in local testing guidelines and routine 
practice for respiratory screening, or reflect age-based 
screening practices (e.g. the majority of Hungarian and 
Swedish samples derived from a population > 25 years 
of age).
The final analysis examined the association between 
the start of epidemic periods as calculated by the MEM 
model and the geographical location of the country as 
determined by latitude. Geographical location has not 
been thought to be of importance in the progression 
of  M. pneumoniae  infection, but our data suggests 
that more northern countries experience the start of 
epidemic periods earlier than those in the south. This 
association was most clear during the 2011/12 epi-
demic period, but also held true for the subsequent 
epidemic periods of 2014/15 and 2015/16. Previous 
national-based studies have shown epidemics to be 
polyclonal in nature [25-30]. Establishing whether the 
microbiological nature of the epidemics across Europe 
are clonal or not, may be beneficial and influence 
future sentinel surveillance design. The impact of cli-
matic factors on  M. pneumoniae  infections has yet to 
be investigated.
Limitations
A number of limitations are apparent. First, because 
of the variable reporting methods of each country, 
specific case definitions were not considered and 
de-duplication methodologies were not imposed but 
rather set at submitter-specific level. Overall, reported 
testing activity or testing-incidence was very different 
between countries (regions), and conclusions based 
on analysis across countries must be considered with 
caution. Ireland did not provide a complete dataset 
because they only investigated  M. pneumoniae  in 
patients who were 24 years of age and under. The true 
number of positive individuals from this population 
is therefore likely to be underestimated. Second, the 
data from some countries may not be fully representa-
tive of the country as a whole. For example, data from 
Germany and France was obtained from a single region 
within each country and how representative this is of 
national coverage is unknown. Third, the data exam-
ining the distribution of detections stratified by age 
group should be interpreted with a level of caution. 
The age categories did not contain equal weighting of 
age groups; for example, there were fewer ages encom-
passed in the 0 to 4 years group compared with older 
age groups such as the 25 to 44 years group. Finally, 
this data did not take the subtypes of  M. pneumo-
niae that have been described into account.
Possible clinical impact
The comparative nature of this study has highlighted 
a number of interesting points with regards to trends 
in the testing and epidemiology of  M. pneumo-
niae  infections. First, cases may be under-detected 
in countries because of limitations in the age groups 
examined for the infection. A number of countries 
showed a skew towards patients > 25 years of age 
and Belgium, Denmark, France, the United Kingdom 
(excluding Northern Ireland) and Israel showed a 
bimodal distribution, suggesting investigations for  M. 
pneumoniae, although of importance in young children, 
should not be restrictive and that consistent testing 
guidelines are required. It would be beneficial to have 
an agreed international case definition for infection 
with M. pneumoniae.
This study also highlights a lack of antimicrobial 
resistance testing and surveillance of  M. pneumo-
niae, resulting in a limited evidence base on resistance 
to guide therapy. Without active coordinated 
monitoring, it will not be possible to track changes in 
resistance profiles and the emergence of high-level 
macrolide resistant clones. There is an absence of a 
structured European level surveillance and resistance 
monitoring for this infection, despite the high levels 
of resistance in some global areas. In the authors’ 
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opinion, structured surveillance should be imple-
mented in Europe.
Finally, the observation relating to association 
between northern latitudes and earlier epidemic start 
week may suggest the need for another more focused 
study. It would be interesting to assess the potential 
value of a rapid, real-time reporting system of M. pneu-
moniae infections across Europe. Such a system could 
possibly aid in future epidemiological studies and 
resistance monitoring, and help to predict the M. pneu-
moniae epidemic season throughout the continent.
Conclusion
As this large study demonstrates, there is currently 
no standardised method for detecting  M. pneumo-
niae infection among patients and macrolide resistance 
screening is sporadic in European countries despite 
high levels in some areas globally. A wave of epidemics 
from more northern latitudes to the more southern 
ones occurs during epidemic years and the reason for 
this is not known. There is a need for testing guidelines 
and standardised international control material for use 
in testing. The potential value of a co-ordinated inter-
national surveillance and macrolide resistance moni-
toring system needs to be further addressed.
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